Novel acyl hydrazides of the formula (I), in which R1 - R9 have the meaningsdefined in claim 1, are SGK inhibitors and can be used for the treatment ofSGK-induced diseases and conditions such as diabetes, obesity, metabolicsyndrome (dyslipidemia), systemic and pulmonary hypertension, cardiovasculardiseases and kidney diseases, and generally any types of fibroses andinflammatory processes.